Evidence map›Paper›PMID 34657240›Full record

ArticleMolecular and cellular biochemistry2022

DAL-1/4.1B promotes the uptake of exosomes in lung cancer cells via Heparan Sulfate Proteoglycan 2 (HSPG2).

Shuai Zhang, Min Guo, Tingting Guo, Mingyan Yang, Jiaqi Cheng, Chenyang Cui, Jie Kang, Jiajia Wang, Yuanru Nian, Wenjie Ma and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Shuai ZhangSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Min GuoKey Laboratory of Prenatal Diagnostic Medicine of Jiaozuo Municipal Health Commission, Genetic and Prenatal Diagnosis Center, Maternal and Child Health Hospital of Jiaozuo, Jiaozuo, 454000, Henan, China.
Tingting GuoSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Mingyan YangSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Jiaqi ChengSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Chenyang CuiSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Jie KangSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Jiajia WangSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Yuanru NianSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Wenjie MaSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Haibin WengLiaocheng People's Hospital Emergency Department, Liaocheng, 252000, Shandong, China. 704759227@qq.com.
Haibo WengSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China. whb@zzu.edu.cn.ORCID http://orcid.org/0000-0002-9527-1289
Zhengzhou University · CNJiaozuo University · CN

Funding

the National Natural Science Foundation of China 81970173
6 · The paper itself

Abstract

DAL-1/4.1B is frequently absent in lung cancer tissues, which is significantly related to the occurrence and development of lung cancer. In this research, we found that DAL-1/4.1B affected the uptake of exosomes by lung cancer cells. When the expression of DAL-1/4.1B increased and decreased, the ability of exosome uptake enhanced and attenuated correspondingly. And we found that when cells were treated with different vesicles uptake inhibitors (chlorpromazine, methyl-β-cyclodextrin (MβCD), cytochalasin D, chloroquine and heparin) and heparinase (HSPE), only heparin and HSPE counteracted the uptake enhancement effect caused by DAL-1/4.1B. Therefore, we speculated that DAL-1/4.1B might promote the uptake of exosomes through the heparan sulfate proteoglycans (HSPGs) pathway. After screening the expression of HSPGs and HSPE in H292 cells, the expression of heparan sulfate proteoglycan 2 (HSPG2) increased with overexpression of DAL-1/4.1B and decreased with knockdown of DAL-1/4.1B. Meanwhile, exosome uptake decreased with HSPG2 knockdown in H292 and DAL-1/4.1B-overexpressing H292 cells. Moreover, knockdown of DAL-1/4.1B and HSPG2 in lung cancer A549 cells resulted in a similar decrease in exosome uptake, and the expression of HSPG2 was also decreased with DAL-1/4.1B knockdown. These results indicated that HSPG2 directly affected the uptake of exosomes, while DAL-1/4.1B positively affected the expression of HSPG2. Therefore, DAL-1/4.1B may promote cellular adhesion and inhibit migration in cancer cells.

Indexed as

A549 CellsExosomesHeparan Sulfate ProteoglycansHumansLung NeoplasmsMCF-7 CellsMicrofilament ProteinsNeoplasm ProteinsEPB41L3 protein, humanHeparan Sulfate ProteoglycansMicrofilament ProteinsNeoplasm ProteinsperlecanDAL-1/4.1BExosomeExosome uptakeHSPG2HSPGsLung cancer

Identifiers

PMID34657240
OpenAlexW3206148185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.